Elagolix Sodium Patent Expiration
Elagolix Sodium is Used for managing moderate to severe pain associated with endometriosis. It was first introduced by Abbvie Inc
Elagolix Sodium Patents
Given below is the list of patents protecting Elagolix Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Orilissa | US10537572 | Methods of administering elagolix | Sep 01, 2036 | Abbvie |
| Orilissa | US10682351 | Methods of administering elagolix | Sep 01, 2036 | Abbvie |
| Orilissa | US11344551 | Methods of treating heavy menstrual bleeding | Mar 14, 2034 | Abbvie |
| Orilissa | US11542239 | Elagolix sodium compositions and processes | Jul 23, 2039 | Abbvie |
| Orilissa | US11690845 | Methods of administering elagolix | Aug 27, 2040 | Abbvie |
| Orilissa | US11690854 | Methods of treating heavy menstrual bleeding | Apr 19, 2038 | Abbvie |
| Orilissa | US11707464 | Methods of treating heavy menstrual bleeding | Mar 14, 2034 | Abbvie |
| Orilissa | US6872728 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jan 25, 2021
(Expired) | Abbvie |
| Orilissa | US7056927 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | Sep 10, 2024 | Abbvie |
| Orilissa | US7176211 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jul 06, 2024
(Expired) | Abbvie |
| Orilissa | US7179815 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Mar 07, 2021
(Expired) | Abbvie |
| Orilissa | US7419983 | Gonadotropin-releasing hormone receptor antagonists and methods related thereto | Jul 06, 2029 | Abbvie |
| Orilissa | US7462625 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jan 25, 2021
(Expired) | Abbvie |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳